Department of Medicine, Division of Dermatology
Letter to the Editor
Medical Subject Headings
Administration, Topical; Aminoquinolines; Biopsy, Needle; Female; Follow-Up Studies; Humans; Hutchinson's Melanotic Freckle; Immunohistochemistry; Melanoma, Amelanotic; Middle Aged; Neoplasm Recurrence, Local; Nose; Risk Assessment; Skin Neoplasms; Treatment Outcome
A melanotic lentigo maligna (ALM) represents a small subset of lentigo maligna (LM) that lacks pigment. At least 2 cases of ALM responsive to imiquimod therapy with short-term follow-up have been reported. We report herein a case of ALM that failed to respond to imiquimod treatment. Furthermore, after therapy was initiated, the ALM began to produce pigment and transformed to LM.
Kathryn J. Martires, Laura Capaldi, Sean F. Pattee, Mary E. Maloney, et al.. "Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production" Vol. 146 Iss. 9 (2010) ISSN: 0003-987X (Linking)
Available at: http://works.bepress.com/mary_maloney/26/